Real-world study of breast cancer treatment with pertuzumab biosimilar
Part of Cancer, Skin clinical trials.
This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer (a specific type confirmed by lab testing)
- You are at least 19 years old
- Your doctor has decided to give you a pertuzumab biosimilar as part of your regular care (not as part of another research study)
- Your treatment is either before surgery to shrink the tumor, or as your first treatment for cancer that has spread
- You can commit to at least 6 months of follow-up visits and medical record sharing
- You have not had a severe allergic reaction to pertuzumab in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1811 combined with pertuzumab (Perjeta) before surgery for patients with HER2-positive breast cancer that has not spread beyond the breast and nearby lymph nodes. The goal is to shrink the cancer before surgery and improve outcomes.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.